Interventions for valvular disease and heart failure

A pilot study with the TriGUARD 3 cerebral embolic protection device

EuroIntervention 2020;16:507-509. DOI: 10.4244/EIJ-D-19-00741

Pedro G. Magalhaes¹^,²^,³, MD; Nynke H. M. Kooistra⁴, MD, MSc; Geert E.H. Leenders², MD, PhD; Pauliina M. Margolis⁵, MD, PhD; Alexandra J. Lansky⁶, MD, PhD; Adriaan O. Kraaijeveld², MD, PhD; Michiel Voskuil², MD, PhD; Pieter R. Stella², MD, PhD

1. Department of Cardiology, Centro Hospitalar de Trás-os-Montes e Alto Douro, Hospital of Vila Real, Vila Real, Portugal; 2. Department of Interventional Cardiology, Heart & Lungs Division, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands; 3. Sociedade Portuguesa de Cardiologia, Lisbon, Portugal; 4. Department of Cardiology, Heart & Lungs Division, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands; 5. Keystone Heart, Tampa, FL, USA; 6. Cardiovascular Medicine, Heart and Vascular Clinical Research Program, Yale University School of Medicine, New Haven, CT, USA

Introduction

A substantial proportion of patients submitted to transcatheter aortic valve replacement (TAVR) continues to be affected by procedure-related neurological events, with 30-day clinical stroke rates in the range of 4-7%. Also, routine neuroimaging studies reveal that ischaemic cerebral infarction caused by showers of cerebral emboli during valve instrumentation and placement affect virtually all patients undergoing TAVR1,2,3.

In order to prevent these embolic phenomena, several cerebral embolic protection devices (CEPD) have recently been developed. Their use during TAVR has been associated with improved early imaging and clinical neurological outcomes1.

The TriGuard™ and TriGuard™ HDH (...

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Share on Facebook Share on Twitter Share on Linkedin